x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist

The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD

science life sciences

All Episodes

22:31

246: Why Your Shake Flask Culture Doesn't Scale: OTR,...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/23

Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing. Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay developme...

en-us

27:25

245: Why Your Shake Flask Culture Doesn't Scale: OTR,...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/21

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper? Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreacto...

en-us

17:45

244: Prevent the Delays That Derail Biologics Tech...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/16

When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? Tech transfers aren’t a black box. They’re complex, but solvable with the right mindset and playbook. In this episode, David Brühlmann explores the practical side of tech transfer and scale-up within the biotech industry. With more than 15 years of experience, he shares personal stories and industry-tested frameworks that help demystify the comple...

en-us

14:47

243: Turn Tech Transfer from a Gamble into a Managed...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/14

What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document? Too often, biotech teams discover too late that their “proven” process is just an illusion, propped up by undocumented tricks and missing critical parameters. In this episode, David Brühlmann strips down the assumptions behind scale-up and tech transfer, exposing the silent risks that threaten CMC milestones and market launches alike. After 15 years guiding biotech projects from bench to cli...

en-us

17:46

242: DMSO in Cell Therapy: Why Viability Scores Hide...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/09

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish? This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from...

en-us

20:26

241: DMSO in Cell Therapy: Why Viability Scores Hide...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/07

Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical. Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He n...

en-us

18:47

240: Continuous Microbial Manufacturing: From Genetic...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/04/02

Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position. In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade ...

en-us

27:21

239: Continuous Microbial Manufacturing: From Genetic...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/31

What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing? Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few...

en-us

13:59

238: High-Throughput Microbial Screening: Avoiding...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/26

For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream. David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, un...

en-us

19:42

237: High-Throughput Microbial Screening: Avoiding...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/24

Why do so many promising biotech ideas stall long before they reach the clinic or marketplace? For many, the answer lies hidden in the earliest phase of bioprocess development: upstream processing. It’s where strain selection, media optimization, and culture conditions set the stage for everything that follows. Yet, the smallest missteps here can snowball into expensive roadblocks downstream. This episode of Smart Biotech Scientist Podcast zeros in on why smart screening strategies and the ri...

en-us

18:50

236: Plant-Based Biomanufacturing: How Molecular...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/19

For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months. Meet Waranyoo Phoolcharoen...

en-us

26:35

235: Plant-Based Biomanufacturing: How Molecular...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/17

Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants. Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plan...

en-us

22:06

234: Why Most Bioprocess Automation Projects Fail...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/12

Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions. Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the...

en-us

21:07

233: Why Most Bioprocess Automation Projects Fail...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/10

Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot. In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation. Highlights from the episode: Why biotech's "special case...

en-us

18:16

232: From IND to BLA: The Biologics CMC Decisions...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/05

How solid is your CMC foundation—and what happens if it cracks under pressure? David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His “house building” approach demystifies CMC...

en-us

19:39

231: From IND to BLA: The Biologics CMC Decisions...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/03/03

Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later. Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across som...

en-us

19:00

230: Cyanobacteria Biomanufacturing: Achieving...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/02/26

What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures. In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing ...

en-us

25:11

229: Cyanobacteria Biomanufacturing: Achieving...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/02/24

The chemicals industry remains locked into carbon-intensive, fossil-based manufacturing. Even engineered microbes like yeast or E. coli depend on expensive sugar feedstocks while generating significant waste. What if a photosynthetic organism could eliminate those constraints entirely—while commanding premium pricing as "ocean-derived"? On the Smart Biotech Scientist Podcast, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, reveals how a recently discovered fast-growing marine cyanobact...

en-us

15:52

228: Media-Based Glycan Engineering for Biosimilars:...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/02/17

How early in process development should you address glycosylation? This episode presents the case for co-optimizing glycan profiles with productivity from initial process characterization. Deferring glycosylation characterization until after titer targets are met introduces risk: quality attribute gaps discovered late in development force process re-optimization, extended timelines, and potential cell line reselection. Media supplementation enables earlier intervention—tuning glycan distribut...

en-us

16:34

227: Media-Based Glycan Engineering for Biosimilars:...

Smart Biotech Scientist | The CMC and Bioprocessing... ·

2026/02/10

When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering. In this episode, David Brühlmann pres...

en-us

214 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter